Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD – has no relevant financial relationships to disclose in relation to the content of this activity.
Emir Hadzic, PhD – has no relevant financial relationships to disclose in relation to the content of this activity.
Roy S. Herbst, MD, PhD – is a consultant for AstraZeneca, Lilly, Genentech/Roche, Gilead, Merck and Pfizer; receives grant/research support from Genentech and Merck; and is a member of the scientific advisory boards for Biothera, Diatech, and Kolltan.
Josiah Land, PharmD, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.
Rachael B. Pollina, MS, MSN, RN, OCN®, FNP-BC – has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:
Hossein Borghaei, DO – is a consultant for Bristol-Myers Squibb, Celgene, EMD-Serono, Genentech, Lilly, and Pfizer, and receives research/grant support from Celgene, Merck, and Millennium.
Paul A. Bunn, Jr, MD, FASCO – is a consultant for AstraZeneca, Boehringer Ingelheim, Clovis, and Genentech.
David S. disclosures to come
Justin F. Gainor, MD – is a consultant for ARIAD, Bristol-Myers Squibb, Boehringer Ingelheim, Clovis, Genentech, Incyte, Loxo, Merck, Novartis, and Theravance.
David R. Gandara, MD – is a consultant for ARIAD, AstraZeneca, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Mirati, Novartis, and Pfizer, and receives research/grant support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Clovis, Genentech, Johnson and Johnson, Lilly, Merck, and Novartis.
Ramaswamy Govindan, MD – is a consultant for ARIAD, Astellas, Bayer, Celgene, Clovis, Genentech, GlaxoSmithKline, Helsinn, and Roche, and is a member of the speakers’ bureaus for Baxalta, Celgene, Pfizer, and Roche.
Fred R. Hirsch, MD, PhD – has participated on scientific advisory boards for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Lilly, Merck, Pfizer, and Ventana. His institution, the University of Colorado, receives grant/research support from Amgen, Bayer, Bristol-Myers Squibb, Genentech/Roche, Lilly, and Merck.
Mark G. Kris, MD, FACP, FACCP – has no relevant financial relationships to disclose in relation to the content of this activity.
Corey J. Langer, MD – is a scientific advisor for Abbott, Abraxis Oncology (Celgene), ARIAD, AstraZeneca, Bayer HealthCare Pharmaceuticals/Onxy Pharmaceuticals, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, CarisDx, Clariant, Clovis, Lilly, Genentech, ImClone Systems, Novartis, Pfizer, and Synta. He receives institutional grant/research support from Advantagene, Ariad, Bristol-Myers Squibb, Clovis, Lilly, Genentech, GlaxoSmithKline, ImClone Systems, Inovio, Merck, Nektar, OSI, and Pfizer. He is a member of Data and Safety Monitoring Committee for Amgen, Incyte, Peregrine, SWOG, and Synta..
Vassiliki A. Papadimitrakopoulou, MD – is a consultant for ARIAD, AstraZeneca, Biothera, Bristol-Myers Squibb, Genentech, Johnson and Johnson, and Merck. She receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Johnson and Johnson, Merck, and Novartis.
Suresh S. Ramalingam, MD – is a consultant for Abbvie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Merck, and Novartis.
Naiyer Rizvi, MD – is a consultant for AstraZeneca, Merck, Novartis, and Roche, and is a shareholder/co-founder of Gritstone Oncology.
Lecia V. Sequist, MD, MPH – is a consultant for Ariad, AstraZeneca, Boehringer Ingelheim, Clovis, Merrimack, and Novartis.
Mark A. Socinski, MD – receives grant/research support from Bristol-Myers Squibb, Celgene, Clovis, Genentech, and Pfizer, and is a member of the speakers’ bureaus for Bristol-Myers Squibb, Celgene, and Genentech.
Thomas E. Stinchcombe, MD – is a consultant for ARIAD, Boehringer Ingelheim, Bristol-Myers Squibb, and Helsinn, and receives grant/research support from Bristol-Myers Squibb, Genentech, and Merck Serono.
Howard (Jack) West, MD – is a consultant for AstraZeneca, Boehringer Ingelheim, Genetech/Roche, Guardant, and Trovagene, and is a member of the speakers’ bureau for Genentech/Roche.

Reviewers:
Corey J. Langer, MD – is a scientific advisor for Abbott, Abraxis Oncology (Celgene), ARIAD, AstraZeneca, Bayer HealthCare Pharmaceuticals/Onxy Pharmaceuticals, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, CarisDx, Clariant, Clovis, Lilly, Genentech, ImClone Systems, Novartis, Pfizer, and Synta. He receives institutional grant/research support from Advantagene, Ariad, Bristol-Myers Squibb, Clovis, Lilly, Genentech, GlaxoSmithKline, ImClone Systems, Inovio, Merck, Nektar, OSI, and Pfizer. He is a member of Data and Safety Monitoring Committee for Amgen, Incyte, Peregrine, SWOG, and Synta..
Vassiliki A. Papadimitrakopoulou, MD – is a consultant for ARIAD, AstraZeneca, Biothera, Bristol-Myers Squibb, Genentech, Johnson and Johnson, and Merck. She receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Johnson and Johnson, Merck, and Novartis.
Sarah S. Peters, PharmD, MPH, BCOP – is a consultant for Genentech, and is a member of the speakers’ bureaus for Boehringer-Ingelheim, Lilly, Merck, and Pfizer.
Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP - has no relevant financial relationships to disclose in relation to the content.